UPMC Physician Resources

Archives for Heart and Vascular

25th Annual Transcatheter Cardiovascular Therapeutics Scientific Symposium

Krishna Tummalapalli, MD, is principal investigator at UPMC Shadyside for the SAFE PCI clinical trial conducted exclusively in women, which suggests that an initial strategy of using the radial artery in the arm as the entry point for cardiac catheterization or percutaneous coronary intervention (PCI) in women has potential for reducing bleeding complications. SAFE-PCI for Women is the first registry-based randomized trial in the United States and the first multicenter trial, led by Sunil Rao, MD, of Duke University, comparing radial with femoral access in the U.S., and its primary findings were presented recently at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.

 

Watch Dr. Tummalapalli discuss the findings.


 

Florida Valve International

Join the world’s leaders in valvular intervention and surgery as we debate the latest controversies in valve treatment and explore the hottest innovations that are set to reshape our collaborative multidisciplinary specialty.Florida Valve International will be taking place this year from March 7-9, 2014 in Miami, Florida.

Abstracts are now being accepted.

Hear from Course Co-Director, Vinay Badhwar, MD (Pittsburgh, PA, USA).

Visit our Florida Valve International conference page for more information.

11th Annual Pittsburgh Vascular Symposium Recap

The 11th Annual Pittsburgh Vascular, Symposium Helping Cardiologists and Vascular Surgeons Cross the Divide, took place Septemeber 12-14, 2013 in Pittsburgh, Pa.

The Pittsburgh Vascular Symposium was designed to help provide evaluation and critique of the current and future standards of care in the treatment of the cardiac and vascular patient with respect to medical management,as well as endovascular and open therapies for the primary care provider, cardiologists, interventionalists and the vascular surgeon. The Symposium also focused on new developments in technology, as well as surgical techniques, and the controversies as well as accepted practices.

Hear Symposium wrap ups from two of UPMC’s presenters.

Steven Leers, MD
Medical director, UPMC Vascular Laboratories
Vascular surgeon, UPMC Heart and Vascular Institute
Associate professor of surgery
Lower Extremity Bypass: Is it Outdated?
Vascular Lab Session (RPVI) Welcome / Content Outline

 

Luke Marone, MD
Chief, Division of Vascular Surgery at UPMC Passavant
Associate professor of surgery
Novel and Upcoming Technologies for the Revascularization of Ischemic Limb

 

 

 

Controversies in Mitral Valve Repair

Would you like to know the latest thoughts on mitral valve repair? As part of the recent annual meeting of The Society of Thoracic Surgeons, UPMC’s Vinay Badhwar, MD,  moderated a panel of surgeon leaders as they discussed topics ranging from handling functional mitral regurgitation to low ejection fraction.

Clotting Time as a Monitoring Tool for Heparin Management in ECMO

Peter Wearden, MD, PhD, director, pediatric mechanical cardiopulmonary support, Children’s Hospital of Pittsburgh of UPMC, discusses recent findings on the use of activated clotting time as a monitoring tool for heparin management in ECMO.  These findings were recently published in Pediatric Critical Care Medicine.

Hear about the recently published paper from Dr. Wearden:

Optical Coherence Tomography for Detection of Cardiac Allograft Vasculopathy (OCTCAV Study)

Sameer Khandhar, MD, presented “Optical Coherence Tomography for Detection of Cardiac Allograft Vasculopathy (OCTCAV Study),” at the International Society for Heart and Lung Transplantation’s 32nd Annual Meeting and Scientific Sessions in Prague, Czech Republic. He discussed the results of this study which explored optical coherence tomography for earlier detection and more accurate characterization of coronary allograft vasculopathy.

http://www.sciencedirect.com/science/article/pii/S1053249812002823

Hear more about this work from Dr. Khandhar:

Alemtuzumab Induction Facilitates Steroid-Free Immunosuppression in Human Cardiac Transplantation: Four-Year Outcomes

Jeffrey Teuteberg, MD, presented “Alemtuzumab Induction Facilitates Steroid-Free Immunosuppression in Human Cardiac Transplantation: Four Year Outcomes,” at the International Society for Heart and Lung Transplantation’s 32nd Annual Meeting and Scientific Sessions in Prague, Czech Republic. He discussed routine induction therapy with alemtuzumab (C-1H) prior to cardiac transplantation (CTX) which allows for steroid free, lower intensity maintenance immunosuppression.

http://www.sciencedirect.com/science/article/pii/S105324981200215X

Hear more about this work from Dr. Teuteberg:

Prediction of Events in Patients with Advanced Heart Failure: Application of the Seattle Heart Failure Model to the MEDAMACs Population

Jeffrey Teuteberg, MD, presented “Prediction of Events in Patients with Advanced Heart Failure: Application of the Seattle Heart Failure Model to the MEDAMACs Population,” at the International Society for Heart and Lung Transplantation’s 32nd Annual Meeting and Scientific Sessions in Prague, Czech Republic. He discussed the MEDAMACS pilot study, which enrolled patients aged 18-80 with heart failure : > 12 months on optimal therapy, EF < 30%, and 2 hospitalizations in the past year or 1 hospitalization and 1 high risk feature. The Seattle Heart Failure Model (SFHM) has not been previously assessed in a large cohort with non-inotrope dependent advanced heart failure.

http://www.sciencedirect.com/science/article/pii/S1053249812001805

Hear more about this presentation from Dr. Teuteberg:

Implant Strategies for Continuous-Flow LVAD Therapy in INTERMACS – Impact on Outcomes and Variability over Time

Jeffrey Teuteberg, MD, presented “Implant Strategies for Continuous Flow LVAD Therapy in INTERMACS – Impact on Outcomes and Variability over Time,” at the International Society for Heart and Lung Transplantation’s 32nd Annual Meeting and Scientific Sessions in Prague, Czech Republic. He discussed how continuous flow (CF) left ventricular assist device (LVAD) implant strategy impacts candidate selection, reimbursement, and constrains trial design. The research assessed the evolution of strategies for CF LVADs and their impact on outcomes.

http://www.sciencedirect.com/science/article/pii/S1053249812000204

Dr. Teuteberg discusses this presentation below:

UPMC-led Study Finds Improvements in Pacemaker Lead Placement Get Better Results for Heart Failure Patients

Special advanced ultrasound images of the heart to determine the ideal location for implanting a biventricular pacemaker’s left ventricular lead, rather than non-specific placement, can reduce the rates of death or hospitalization for some heart failure patients, according to a study led by researchers at UPMC.

Samir Saba, MD, director of cardiac electrophysiology and principal investigator on the study, which was funded by the American Heart Association, recently presented the study’s findings at Heart Rhythm 2012, the Heart Rhythm Society’s 33rd Annual Scientific Sessions in Boston. View the news release.

The technique used in this study consisted of a special kind of echocardiography called ‘speckle tracking’ which was pioneered by Dr. Saba’s colleague and co-investigator John Gorcsan at UPMC. It basically examines the time to peak contraction in multiple areas of the left ventricle and determines the site of latest mechanical activation which is then used as a target for lead placement and pacing in this study.

Other collaborators on the study were David Schwartzman, M.D.; Sandeep Jain, M.D.; and Evan Adelstein, M.D.; Josef Marek, M.D.; Pamela White, R.N.; Olusegun A. Oyenuga, M.D.; and Prem Soman, M.D., all from the University of Pittsburgh School of Medicine.

Hear more about the study directly from Dr. Saba: 

 

Page 3 of 4:« 1 2 3 4 »
  • Make A Referral

    To refer a patient, call UPMC’s 24-hour physician referral service at 1-800-544-2500 or e-mail us.
  • Information for your Patients

    UPMC’s Clinical Services page provides information for your patients on services, conditions, and treatments.